BUB1B MITOTIC KINASE DRIVES THERAPY RESISTANT PROSTATE CANCER
M. J. Martinez, C Blanco, Nahuel Peinetti, RLZ Lyles, MV Revuelta, Kerry L. Burnstein
This study identifies BUB1B as a driver of castration-resistant prostate cancer and shows its role in enzalutamide resistance, suggesting it as a therapeutic target.
bioRxiv · Nov 9, 2025 · PreprintCancer Biology